Video

Bispecifics in Multiple Myeloma: Dosing and Transition of Care

Author(s):

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB

A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.

Related Videos
Robert M. Rifkin, MD, FACP
4 experts are featured in this series.
Bradley McGregor, MD,
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Related Content
Cancer | Image Credit: © catalin - stock.adobe.com
January 22nd 2025

Dana-Farber Brigham Cancer Center Recognized for Exceptional Outcomes in Adult Donor Stem Cell Transplants for Fifth Consecutive Year

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Multiple Myeloma | stock.adobe.com
January 19th 2025

Retrospective Study Highlights Real-World Uptake of Bispecific Antibodies in R/R Multiple Myeloma

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

David S. Siegel, MD, PhD, chief of the Division of Multiple Myeloma at John Theurer Cancer Center, Hackensack University Medical Center, New Jersey
January 17th 2025

Preliminary Efficacy, Safety Data Drive Further Exploration of Mezigdomide-Based Combinations in R/R Myeloma

Toni Choueiri, MD
January 16th 2025

Dana-Farber and Gustave Roussy Announce 2025 Transatlantic Exchange Scientific Program to Focus on Radioligand Therapy